Hypomethylating agents are a widely used treatment option in acute myeloid leukemia secondary to myeloproliferative neoplasms (MPNs), but careful monitoring of thromboembolic risk is needed for ...

Among a cohort of 88 patients with acute myeloid leukemia who received hypomethylating agents with venetoclax prior to allogeneic hematopoietic cell transplant, 85% had achieved morphologic complete ...

Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR). Evaluation ...

Factors associated with lower odds of receiving 4 or more cycles of HMAs included treatment with decitabine, having 2 to 3 cytopenias, and being nursing home residents. HealthDay News — Few patients ...

Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis. Background: Myelodysplastic syndrome (MDS) is ...

Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...

Hypomethylating agents (HMAs) are underutilized in high-risk MDS patients, especially among older, female, and non-White individuals. Only 16.1% of Medicare patients with newly diagnosed MDS received ...

Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS) - a group of disorders where there is insufficient production of healthy ...

Intensive induction chemotherapy and HMA/VEN showed similar adjusted survival outcomes in older patients with NPM1-mutant AML. Composite complete remission rates were comparable between IC and HMA/VEN ...

PLEASANTON, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (Astex) today announce that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for the oral ...